Moderna Wins FDA Approval for mFLUSIVA mRNA Flu Vaccine for Adults 50+ 
Oil Prices Fall as Middle East Exports Recover, G7 Eases Supply Fears 
Iran Tanker Attacks Surge as Hormuz Oil Flows Near Prewar Levels 
Gold Prices Rise as Dollar Weakens, Treasury Yields Ease 
LG Electronics Shares Slide as Q3 Profit Misses Estimates 
Samsung, SK Hynix Shares Fall Ahead of Q3 Earnings 
Paramount-Warner Bros $110 Billion Deal Draws Antitrust Backlash 
Sanofi, Regeneron Expand Drug Partnership in $8 Billion Deal 
SpaceX Seeks $40 Billion for Nvidia AI Chips 
Moderna Short Sellers Hit With $4.8 Billion Loss as Stock Soars 
US Supreme Court Revives Trump Administration Voter Citizenship Database 
S&P 500 Hits Record High as AI Rally Lifts Wall Street 
Ukraine Faces $56 Billion Budget Gap as War Costs Soar 
Litecoin Marks 15 Years as Grayscale Backs LTC ETF Push 
GSK Unveils $2.52 Billion Cost-Cutting Plan to Accelerate Drug Pipeline 
Novartis M&A Strategy Faces Investor Scrutiny After Drug Setbacks 
Add as a preferred source on Google
Abbott Laboratories faces a criminal investigation by the Justice Department, after its recall of formulas due to complaints of bacterial infections exacerbated a shortage that began due to pandemic-induced supply chain issues.
The Justice Department was investigating conduct at Abbott’s plant in Sturgis, Michigan,
According to an Abbott spokesman, they are fully cooperating with the Justice Department without specifying what aspect of the company is under scrutiny.
In February 2022, Abbott, the biggest US supplier of baby formula, recalled Similac and other infant formula products produced at its Michigan facility after reports of bacterial infections in babies who had consumed products made there.
The US Food and Drug Administration found "shocking" results during an inspection, such as cracks in vital equipment, inadequate hand-washing, and evidence of previous bacterial contamination.
The plant has since reopened.
